Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31415219 | 1.00 | MAPT (0.51) | MAPTKDM4EPTPN7ALDH1A1HIF1A | |
| SCHEMBL6968807 | 0.88 | RAPGEF3 (0.53) | MAPTPTPN7ALDH1A1MEN1KMT2A | |
| SCHEMBL213877 | 0.86 | PTPN7 (0.51) | MAPTPTPN7ALDH1A1MEN1KMT2A | |
| SCHEMBL19212367 | 0.84 | MAPT (0.57) | MAPTKDM4EALDH1A1HIF1AMEN1 | |
| SCHEMBL17066157 | 0.82 | MAPT (0.57) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL31415261 | 0.82 | MAPT (0.57) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL11188562 | 0.82 | MCL1 (0.59) | MAPTPTPN7ALDH1A1MEN1KMT2A | |
| SCHEMBL30949342 | 0.82 | PARP1 (0.49) | MAPTPTPN7ALDH1A1MEN1KMT2A | |
| SCHEMBL17935270 | 0.81 | MAPT (0.51) | MAPTKDM4EALDH1A1HIF1AMEN1 | |
| SCHEMBL14334126 | 0.80 | ALDH1A1 (0.49) | MAPTKDM4EALDH1A1HIF1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-15 | — | — | US | disclosed |
| EP-3105209-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3105210-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-9957235-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-01 | — | — | US | disclosed |
| US-9951027-B2 | Benzimidazol-2-amines as MIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20170197921-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197922-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| EP-3105209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-21 | — | — | EP | disclosed |
| EP-3105210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015121209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | HRH1, HRH2, HRH3 | MAPT 3046/4885KDM4E 1923/4885PTPN7 3445/4885 |
| US-20170197922-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | HRH1, HRH2, HRH3 | MAPT 3055/4885KDM4E 1954/4885PTPN7 3443/4885 |
| US-20170197921-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | HRH1, HRH2, HRH3 | MAPT 3046/4885KDM4E 1923/4885PTPN7 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.